329 related articles for article (PubMed ID: 18284419)
21. Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.
Chow SK; Casadevall A
Vaccine; 2011 Feb; 29(10):1891-8. PubMed ID: 21238568
[TBL] [Abstract][Full Text] [Related]
22. Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides.
Klutts JS; Doering TL
J Biol Chem; 2008 May; 283(21):14327-34. PubMed ID: 18347023
[TBL] [Abstract][Full Text] [Related]
23. [The role of Angelica polysaccharides in inducing effector molecule release by peritoneal macrophages].
Yang XB; Mei QB; Zhou SY; Teng ZH; Wang HF
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov; 20(6):747-9. PubMed ID: 15555452
[TBL] [Abstract][Full Text] [Related]
24. Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.
Chang ZL; Netski D; Thorkildson P; Kozel TR
Infect Immun; 2006 Jan; 74(1):144-51. PubMed ID: 16368967
[TBL] [Abstract][Full Text] [Related]
25. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan.
Yauch LE; Lam JS; Levitz SM
PLoS Pathog; 2006 Nov; 2(11):e120. PubMed ID: 17096589
[TBL] [Abstract][Full Text] [Related]
26. Immunosuppression, interleukin-10 synthesis and apoptosis are induced in rats inoculated with Cryptococcus neoformans glucuronoxylomannan.
Chiapello LS; Baronetti JL; Aoki MP; Gea S; Rubinstein H; Masih DT
Immunology; 2004 Nov; 113(3):392-400. PubMed ID: 15500627
[TBL] [Abstract][Full Text] [Related]
27. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
[TBL] [Abstract][Full Text] [Related]
28. Immunomodulatory Role of Capsular Polysaccharides Constituents of
Decote-Ricardo D; LaRocque-de-Freitas IF; Rocha JDB; Nascimento DO; Nunes MP; Morrot A; Freire-de-Lima L; Previato JO; Mendonça-Previato L; Freire-de-Lima CG
Front Med (Lausanne); 2019; 6():129. PubMed ID: 31275938
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms for induction of immunosuppression during experimental cryptococcosis: role of glucuronoxylomannan.
Chiapello L; Iribarren P; Cervi L; Rubinstein H; Masih DT
Clin Immunol; 2001 Jul; 100(1):96-106. PubMed ID: 11414750
[TBL] [Abstract][Full Text] [Related]
30. Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.
Nimrichter L; Frases S; Cinelli LP; Viana NB; Nakouzi A; Travassos LR; Casadevall A; Rodrigues ML
Eukaryot Cell; 2007 Aug; 6(8):1400-10. PubMed ID: 17573547
[TBL] [Abstract][Full Text] [Related]
31. Aggregation of Cryptococcus neoformans by surfactant protein D is inhibited by its capsular component glucuronoxylomannan.
van de Wetering JK; Coenjaerts FE; Vaandrager AB; van Golde LM; Batenburg JJ
Infect Immun; 2004 Jan; 72(1):145-53. PubMed ID: 14688091
[TBL] [Abstract][Full Text] [Related]
32. Effect of dominant negative transforming growth factor-beta receptor type II on cytotoxic activity of RAW 264.7, a murine macrophage cell line.
Lee GT; Hong JH; Kwak C; Woo J; Liu V; Lee C; Kim IY
Cancer Res; 2007 Jul; 67(14):6717-24. PubMed ID: 17638882
[TBL] [Abstract][Full Text] [Related]
33. Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1.
De Jesus M; Park CG; Su Y; Goldman DL; Steinman RM; Casadevall A
Med Mycol; 2008 Mar; 46(2):153-62. PubMed ID: 18324494
[TBL] [Abstract][Full Text] [Related]
34. Cryptococcus neoformans inhibits nitric oxide synthesis caused by CpG-oligodeoxynucleotide-stimulated macrophages in a fashion independent of capsular polysaccharides.
Xiao G; Miyazato A; Inden K; Nakamura K; Shiratori K; Nakagawa K; Miyazawa T; Suzuki K; Kaku M; Kawakami K
Microbiol Immunol; 2008 Mar; 52(3):171-9. PubMed ID: 18402599
[TBL] [Abstract][Full Text] [Related]
35. The capsule of the fungal pathogen Cryptococcus neoformans.
Zaragoza O; Rodrigues ML; De Jesus M; Frases S; Dadachova E; Casadevall A
Adv Appl Microbiol; 2009; 68():133-216. PubMed ID: 19426855
[TBL] [Abstract][Full Text] [Related]
36. Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells.
Chaka W; Verheul AF; Vaishnav VV; Cherniak R; Scharringa J; Verhoef J; Snippe H; Hoepelman IM
Infect Immun; 1997 Jan; 65(1):272-8. PubMed ID: 8975923
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of HIV entry by extracellular glucuronoxylomannan of Cryptococcus neoformans.
Yi HA; Panepinto JC; Jacobs A
Microb Pathog; 2012 Jan; 52(1):25-30. PubMed ID: 21983597
[TBL] [Abstract][Full Text] [Related]
38. Structural studies of the capsular polysaccharide of a non-neoformans Cryptococcus species identified as C. laurentii, which was reclassified as Cryptococcus flavescens, from a patient with AIDS.
Ikeda R; Maeda T
Carbohydr Res; 2004 Feb; 339(3):503-9. PubMed ID: 15013387
[TBL] [Abstract][Full Text] [Related]
39. Amentoflavone stimulates apoptosis in B16F-10 melanoma cells by regulating bcl-2, p53 as well as caspase-3 genes and regulates the nitric oxide as well as proinflammatory cytokine production in B16F-10 melanoma cells, tumor associated macrophages and peritoneal macrophages.
Guruvayoorappan C; Kuttan G
J Exp Ther Oncol; 2008; 7(3):207-18. PubMed ID: 19066129
[TBL] [Abstract][Full Text] [Related]
40. The heat shock protein (Hsp) 70 of Cryptococcus neoformans is associated with the fungal cell surface and influences the interaction between yeast and host cells.
Silveira CP; Piffer AC; Kmetzsch L; Fonseca FL; Soares DA; Staats CC; Rodrigues ML; Schrank A; Vainstein MH
Fungal Genet Biol; 2013 Nov; 60():53-63. PubMed ID: 23954835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
